Wall Street analyst estimates for None (BMRA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $5.6M | $5.2M | $6.7M | $7.2M | $18.9M | $5.3M | $5.4M | $5.3M | $4.5M |
| Cost of Revenue | $3.8M | $3.8M | $3.9M | $4.9M | $6.8M | $15.9M | $4.9M | $4.8M | $4.8M | $4.1M |
| Gross Profit | $2.0M | $1.8M | $1.3M | $1.8M | $366285 | $3.0M | $446000 | $611000 | $498000 | $362000 |
| Research & Development | $1.1M | $1.4M | $1.7M | $1.9M | $2.2M | $1.8M | $1.6M | $1.5M | $1.0M | $788000 |
| Selling, General & Admin | $1.8M | $1.8M | $2.0M | $2.3M | $5.7M | $5.7M | $6.1M | $5.5M | $4.6M | $4.9M |
| Operating Expenses | $3.0M | $3.2M | $3.7M | $4.2M | $7.9M | $7.5M | $7.7M | $7.0M | $5.6M | $5.7M |
| Operating Income | -$954633 | -$1.5M | -$2.4M | -$2.4M | -$7.5M | -$4.5M | -$7.2M | -$6.4M | -$5.1M | -$5.3M |
| EBITDA | -$689340 | -$1.2M | -$2.2M | -$1.9M | -$7.1M | -$3.9M | -$6.7M | -$5.6M | -$4.6M | -$4.9M |
| Interest Expense | $282 | $37 | $47 | $9 | $367 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$908561 | -$1.4M | -$2.4M | -$2.3M | -$7.4M | -$4.5M | -$7.1M | -$5.9M | -$5.0M | -$3.8M |
| Income Tax | 0 | $31800 | $24237 | $7390 | $13057 | $23719 | $51000 | $42000 | $1000 | $23000 |
| Net Income | -$908561 | -$1.5M | -$2.4M | -$2.3M | -$7.4M | -$4.5M | -$7.1M | -$6.0M | -$5.0M | -$3.8M |
| EPS | $-0.11 | $-0.17 | $-0.26 | $-0.23 | $-0.54 | $-0.36 | $-0.50 | $-0.36 | $-2.16 | $-1.30 |
| EPS (Diluted) | $-0.11 | $-0.17 | $-0.26 | $-0.23 | $-0.54 | $-0.36 | $-0.50 | $-0.36 | $-2.16 | $-1.30 |
| Shares Outstanding (Diluted) | $8.3M | $8.6M | $9.2M | $10.2M | $11.9M | $12.7M | $14.2M | $16.8M | $2.3M | $2.9M |
Price
| Price | $2.37 |
| Market Cap | $7M |
Related companies: ALZN · CELZ · HSCS · IINN · LFWD · LUCY · PAVM
More sections of BMRA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks